PL2822555T3 - Inhibicja związanej z adaptorem kinazy-1 dla leczenia bólu - Google Patents

Inhibicja związanej z adaptorem kinazy-1 dla leczenia bólu

Info

Publication number
PL2822555T3
PL2822555T3 PL13709722T PL13709722T PL2822555T3 PL 2822555 T3 PL2822555 T3 PL 2822555T3 PL 13709722 T PL13709722 T PL 13709722T PL 13709722 T PL13709722 T PL 13709722T PL 2822555 T3 PL2822555 T3 PL 2822555T3
Authority
PL
Poland
Prior art keywords
pain
inhibition
treatment
associated kinase
adaptor associated
Prior art date
Application number
PL13709722T
Other languages
English (en)
Polish (pl)
Inventor
Thomas Herbert Lanthorn
Katerina Savelieva
Brian Zambrowicz
Original Assignee
Lexicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexicon Pharmaceuticals Inc filed Critical Lexicon Pharmaceuticals Inc
Publication of PL2822555T3 publication Critical patent/PL2822555T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
PL13709722T 2012-03-09 2013-03-06 Inhibicja związanej z adaptorem kinazy-1 dla leczenia bólu PL2822555T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261608849P 2012-03-09 2012-03-09
EP13709722.6A EP2822555B1 (en) 2012-03-09 2013-03-06 Inhibition of adaptor associated kinase 1 for the treatment of pain
PCT/US2013/029258 WO2013134336A2 (en) 2012-03-09 2013-03-06 Inhibition of adaptor associated kinase 1 for the treatment of pain

Publications (1)

Publication Number Publication Date
PL2822555T3 true PL2822555T3 (pl) 2018-04-30

Family

ID=47884616

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13709722T PL2822555T3 (pl) 2012-03-09 2013-03-06 Inhibicja związanej z adaptorem kinazy-1 dla leczenia bólu

Country Status (14)

Country Link
US (4) US20140080834A1 (enExample)
EP (2) EP2822555B1 (enExample)
JP (1) JP2015513557A (enExample)
CN (1) CN104220071A (enExample)
AU (1) AU2013230066A1 (enExample)
CA (1) CA2866145A1 (enExample)
DK (1) DK2822555T3 (enExample)
ES (1) ES2657061T3 (enExample)
HK (1) HK1199814A1 (enExample)
HU (1) HUE036040T2 (enExample)
NO (1) NO2935475T3 (enExample)
PL (1) PL2822555T3 (enExample)
PT (1) PT2822555T (enExample)
WO (1) WO2013134336A2 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2834243T3 (en) 2012-03-09 2018-07-23 Lexicon Pharmaceuticals Inc Pyrazole [1,5-a] pyrimidine-based compounds, compositions comprising them and methods for their use
RU2014140739A (ru) * 2012-03-09 2016-04-27 Лексикон Фармасьютикалз, Инк. Соединения на основе имидазо[1, 2-b]пиридазина, композиции таких соединений и способы их применения
US8901305B2 (en) 2012-07-31 2014-12-02 Bristol-Myers Squibb Company Aryl lactam kinase inhibitors
EP2958924B1 (en) 2013-02-22 2016-12-28 Bristol-Myers Squibb Company 5h-chromeno[3,4-c]pyridines as inhibitors of adaptor associated kinase 1 (aak1)
WO2014175370A1 (ja) * 2013-04-25 2014-10-30 塩野義製薬株式会社 ピロリジン誘導体およびそれらを含有する医薬組成物
JP6434968B2 (ja) * 2013-07-02 2018-12-05 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Rock阻害剤としての三環式ピリド−カルボキサミド誘導体
WO2015006100A1 (en) 2013-07-08 2015-01-15 Bristol-Myers Squibb Company Aryl amide kinase inhibitors
AR097543A1 (es) * 2013-09-06 2016-03-23 Lexicon Pharmaceuticals Inc COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO
TW201542550A (zh) 2013-09-06 2015-11-16 Lexicon Pharmaceuticals Inc 吡唑并[1,5-a]嘧啶基化合物、包含彼之組合物以及使用彼之方法
MX2016002924A (es) * 2013-09-11 2016-06-06 Squibb Bristol Myers Co Inhibidores de cinasa a base de eter arilico.
CN105979950A (zh) * 2013-10-11 2016-09-28 百时美施贵宝公司 吡咯并三嗪激酶抑制剂
ES2701903T3 (es) * 2014-01-31 2019-02-26 Bristol Myers Squibb Co Inhibidores de cinasa a base de quinolina
TW201620911A (zh) * 2014-03-17 2016-06-16 雷西肯製藥股份有限公司 銜接子關聯激酶1之抑制劑、包含其之組成物、及其使用方法
CA2944466C (en) * 2014-04-02 2020-06-09 Bristol-Myers Squibb Company Biaryl kinase inhibitors
US10035777B2 (en) 2014-08-05 2018-07-31 Bristol-Myers Squibb Company Heterocyclic kinase inhibitors
EP3215511B1 (en) 2014-11-06 2024-04-17 Bial-R&D Investments, S.A. Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders
EP3292124B1 (en) 2015-04-10 2019-05-22 Bristol-Myers Squibb Company 6h-isochromeno[3,4-c]pyridines and benzo[c][1,7]naphthyridin-6-(5h)-ones as adaptor associated kinase 1 (aak1) inhibitors
ES2767776T3 (es) 2015-10-01 2020-06-18 Bristol Myers Squibb Co Inhibidores de biaril cinasa
CN112142655A (zh) 2015-10-01 2020-12-29 百时美施贵宝公司 联芳基激酶抑制剂
WO2017176961A1 (en) 2016-04-06 2017-10-12 Lysosomal Therapeutics Inc. Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
KR20180133461A (ko) 2016-04-06 2018-12-14 리소소말 테라퓨틱스 인크. 피라졸로[1,5-a]피리미디닐 카르복스아미드 화합물 및 의학적 장애의 치료에서의 그의 용도
WO2017192930A1 (en) * 2016-05-05 2017-11-09 Lysosomal Therapeutics Inc. SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
US11352328B2 (en) 2016-07-12 2022-06-07 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus
US12419865B2 (en) 2018-12-06 2025-09-23 Arisan Therapeutics Inc. Compounds for the treatment of arenavirus infection
KR102590438B1 (ko) * 2020-10-16 2023-10-18 김홍렬 Pmca 억제제를 포함하는 코로나바이러스 감염 또는 감염 질환의 예방 또는 소독용 조성물
KR102590444B1 (ko) * 2020-10-16 2023-10-18 김홍렬 Pmca 억제제를 포함하는 코로나바이러스 감염 또는 감염 질환의 치료용 조성물
WO2023196584A2 (en) * 2022-04-08 2023-10-12 New York University Endocytosis inhibitors and their use for pain treatment
WO2025225608A1 (en) * 2024-04-23 2025-10-30 Otsuka Pharmaceutical Co., Ltd. Tetrahydropyrazolopyridine derivative
WO2025230262A1 (ko) * 2024-04-29 2025-11-06 심플렉스 주식회사 신규한 헤테로아릴 유도체 및 이의 aak1 억제 용도
WO2026011102A2 (en) * 2024-07-03 2026-01-08 Board Of Regents, The University Of Texas System Compositions and methods for treating cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US20070049591A1 (en) * 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
BRPI0718266A2 (pt) * 2006-10-30 2014-01-07 Novartis Ag Compostos heterocíclicos como agentes anti-inflamatórios.
CA2722418C (en) * 2008-05-13 2013-09-17 Irm Llc Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors
US8461336B2 (en) * 2008-09-04 2013-06-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules

Also Published As

Publication number Publication date
EP3235499A3 (en) 2018-01-17
HK1199814A1 (en) 2015-07-24
US20140080834A1 (en) 2014-03-20
JP2015513557A (ja) 2015-05-14
US20190134037A1 (en) 2019-05-09
HUE036040T2 (hu) 2018-06-28
EP2822555B1 (en) 2017-11-08
CN104220071A (zh) 2014-12-17
WO2013134336A3 (en) 2014-03-06
AU2013230066A1 (en) 2014-09-25
ES2657061T3 (es) 2018-03-01
EP2822555A2 (en) 2015-01-14
CA2866145A1 (en) 2013-09-12
NO2935475T3 (enExample) 2017-12-16
WO2013134336A2 (en) 2013-09-12
EP3235499A2 (en) 2017-10-25
US20160206619A1 (en) 2016-07-21
US20150164899A1 (en) 2015-06-18
DK2822555T3 (en) 2018-02-05
PT2822555T (pt) 2018-01-25

Similar Documents

Publication Publication Date Title
HUE036040T2 (hu) Adaptor-asszociált kináz 1 gátlása fájdalom kezelésére
HUS2200017I1 (hu) Dihidronaftiridinek és rokon vegyületek, amelyek hasznosak kináz inhibitorokként proliferatív betegségek kezelésére
PL2968218T3 (pl) Skojarzenie do leczenia choroby parkinsona
SG10201912275YA (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3kd related disorders
ZA201208646B (en) Pharmaceutical combination for the treatment of pain
ZA201408055B (en) Compositions and methods for the treatment of local pain
SMT201800604T1 (it) Composti per il trattamento di obesita' e metodi di uso degli stessi
HRP20181761T1 (hr) Novi pripravak alfentanila za liječenje akutne boli
ZA201408060B (en) Compositions and methods for the treatment of neurological disorders
PL2817286T3 (pl) Inhibitory kinazy do leczenia raka
IL234796B (en) Compounds for the treatment of diseases related to ischemia-reperfusion
ZA201408061B (en) Compositions and methods for the treatment of neurological disorders
EP2970118A4 (en) COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
GB201207363D0 (en) Compounds for the treatment of metabolic disorders
GB201207359D0 (en) Compounds for the treatment of metabolic disorders
AU2012901199A0 (en) Kinase inhibitors for the Treatment of Cancer
PL399423A1 (pl) Sposób wytwarzania 2'-hydroksydihydrochalkonu
PL399422A1 (pl) Sposób wytwarzania 2',4,4',6'-tetrahydroksydihydrochalkonu
PL398695A1 (pl) Sposób wytwarzania 2'-hydroksydihydrochalkonu